Plain-English translation of NCT07195916 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Solid Tumors research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is a Phase 1 trial testing a new medication called for people with advanced cancers—including kidney cancer, lymphomas, and cutaneous T-cell cancers—that have progressed despite prior treatment. The study focuses on understanding how safe the medication is, what side effects it may cause, and how the body responds to it. Because this is early-stage research, the doses will start low and increase gradually as researchers learn more.
Current treatment options for advanced cancers like refractory lymphomas and kidney cancer are limited, especially after patients have tried other therapies. This medication targets a protein called CD70, which is found on certain cancer cells, and researchers believe blocking it may help slow or stop cancer growth.
You likely qualify if…
You likely don't qualify if…
You will receive the medication at doses determined by the research team, starting with lower doses that may increase over time. The trial involves multiple visits to the study center for check-ups, blood tests, scans, and tissue sampling to monitor how you respond and any side effects. The exact schedule and duration will depend on which part of the study you join and how well you tolerate the treatment.
AI-generated summary from trial data · Oct 2, 2026 · Not medical advice
United States